AiCuris said that the trial has been completed two months earlier than planned.
Indeed, in the later stages of the trial, enrollment had to be restricted as the number of subjects was higher than the number that was required to be enrolled according to the trial protocol.
AiCuris Clinical Development associate director Burkhard Timmler said that they were surprised by the interest in the trial and the number of requests for participation that they received from people infected with herpes simplex virus.
"In spite of available therapeutic options there seems to be a great demand for a new, well tolerated and efficacious drug for people suffering from genital herpes," Timmler said.
AiCuris CEO Rubsamen-Schaeff said that they hope that the results will allow us to determine the efficacious dose of AIC316 and confirm the potential for once daily oral dosing in genital herpes.